STXSStereotaxis, Inc.
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. The company offers robotic magnetic n…
Industry Peers
Medical Instruments & Supplies| Headline | Source | Time |
|---|---|---|
Older | ||
 Stereotaxis (STXS) Q2 2026 Earnings Call Transcript MAGiC catheter adoption accelerates with 12 U.S. sites now performing procedures. | ||
 ISRG's US Procedure Growth Slows: Is ACA Headwind a Temporary Concern? ISRG's US procedure growth slows in Q2, but ACA-related care deferrals may prove temporary as underlying demand and da Vinci 5 adoption remain strong. | ||
 Stereotaxis, Inc. Q2 2026 Earnings Call Summary Moby summary of Stereotaxis, Inc.'s Q2 2026 earnings call | ||
 Stereotaxis Q2 Earnings Call Highlights Stereotaxis (NYSEAMERICAN:STXS) reported second-quarter 2026 revenue of $7.7 million, as growth in sales of its robotic catheter portfolio helped lift recurring revenue to a multiyear high despite lower system revenue and continued supply constraints. Revenue declined from the prior-year quarter be | ||
 Stereotaxis Inc. (STXS) Reports Q2 Loss, Lags Revenue Estimates Stereotaxis (STXS) delivered earnings and revenue surprises of -66.67% and -19.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Teleflex (TFX) Surpasses Q2 Earnings and Revenue Estimates Teleflex (TFX) delivered earnings and revenue surprises of +37.50% and +1.89%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Si-Bone (SIBN) Reports Q2 Loss, Tops Revenue Estimates Si-Bone (SIBN) delivered earnings and revenue surprises of +40.00% and +1.98%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Integer (ITGR) Surges 20.2%: Is This an Indication of Further Gains? Integer (ITGR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. | ||
 Veracyte (VCYT) Q2 Earnings and Revenues Surpass Estimates Veracyte (VCYT) delivered earnings and revenue surprises of +25.58% and +4.13%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Stereotaxis (STXS) Could Be 56% Undervalued After Shelf Registration Filings Assessing Stereotaxis Shelf Registrations and Capital Flexibility Stereotaxis (STXS) has filed multiple shelf registrations that would allow the company to offer up to 128,317,934 common shares, totaling roughly US$205.3 million, putting potential capital raising and dilution firmly on investors radar. See our latest analysis for Stereotaxis. Stereotaxis shares closed at US$1.55 after a sharp 1 day share price decline of 6.06%, extending a year to date share price fall of 33.19% and a 1 year... | ||
 Can ISRG Defend Its Leadership as Global Competition Intensifies? ISRG is countering rising global robotic surgery competition with tiered platforms, AI features and a broad ecosystem focused on value over price. | ||
IInsider Monkey | ||